Min‐Chan Park

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 359 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

Josef S Smolen, Peter Nash, Patrick Durez et al. · The Lancet · 2013 · 354 citations · Full text

Medicine, Immunology, Pharmacotherapy +9

Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification

Min‐Chan Park, Sang‐Won Lee, Park Yb et al. · Scandinavian Journal of Rheumatology · 2005 · 282 citations · Full text

Medicine, Internal Medicine, Immunopathology +12

Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis

Min‐Chan Park, Sang‐Won Lee, Y-B Park et al. · Lara D. Veeken · 2005 · 253 citations · Full text

Veterinary Medicine, Immunology, Autoimmunity +13

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 214 citations

Medicine, Clinical Sciences, Pharmacotherapy +10